Risk of major cardiovascular events, severe hypoglycaemia, and all‐cause mortality for users of insulin degludec versus insulin glargine U100—A Danish cohort study
… In the DEVOTE study, a MACE risk reduction of 12% for people with type 2 diabetes aged 65 to 74 was shown, which is comparable with the 14% risk reduction shown in this study. Both …..... Read More